Oncotarget

Reviews:

Aberrant regulation of FBW7 in cancer

Lixia Wang, Xiantao Ye, Yueyong Liu, Wenyi Wei _ and Zhiwei Wang

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2014; 5:2000-2015. https://doi.org/10.18632/oncotarget.1859

Metrics: PDF 2869 views  |   HTML 4871 views  |   ?  


Abstract

Lixia Wang1,*, Xiantao Ye1,*, Yueyong Liu2, Wenyi Wei2, Zhiwei Wang1,

1 The Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou, China

2 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, USA

* These authors contributed equally to this work

Correspondence:

Wenyi Wei, email:

Zhiwei Wang, email:

Keywords:cancer, tumor suppressor, FBW7, SCF, ubiquitination, oncoprotein

Received: March 13, 2014 Accepted: March 24, 2014 Published: March 25, 2014

Abstract

FBW7 (F-box and WD repeat domain-containing 7) or Fbxw7 is a tumor suppressor, which promotes the ubiquitination and subsequent degradation of numerous oncoproteins including Mcl-1, Cyclin E, Notch, c- Jun, and c-Myc. In turn, FBW7 is regulated by multiple upstream factors including p53, C/EBP-δ, EBP2, Pin1, Hes-5 and Numb4 as well as by microRNAs such as miR-223, miR-27a, miR-25, and miR-129-5p. Given that the Fbw7 tumor suppressor is frequently inactivated or deleted in various human cancers, targeting FBW7 regulators is a promising anti-cancer therapeutic strategy. 


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 1859